Patents Assigned to Optikira LLC
  • Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition
    Patent number: 11649237
    Abstract: Provided herein, inter alia, are substituted imidazo[1,5-?]pyrazine compounds, compositions and methods for treating or preventing an IRE1?-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 16, 2023
    Assignees: Optikira LLC, The Regents of the University of California
    Inventors: Richard M. Keenan, Bradley J. Backes, Dustin J. Maly, Charles Reynolds, Ben Whittaker, Jamie Knight, Jonathan Mark Sutton, George Hynd, Feroz R. Papa, Scott A. Oakes